Document Detail

The role of DMARDs in systemic sclerosis therapy.
MedLine Citation:
PMID:  16987834     Owner:  NLM     Status:  MEDLINE    
The aim of this review is to evaluate the evidence for disease-modifying anti-rheumatic drugs (DMARDs) for treatment of systemic sclerosis (SSc). In the previously published trials, DMARD therapy was usually initiated for severe skin thickening, organ involvement and alveolitis. These studies suggest beneficial effects of methotrexate, azathioprine, ciclosporine A and cyclophosphamide therapy in SSc patients. However, many of these data were derived from retrospective analyses with low numbers of patients, short-term follow-up and often without an appropriate control group. Finally, some of these studies led to inconsistent results. At the present time there is no DMARD therapy of proven efficacy in SSc. Immunosuppressive therapy should only be considered in patients with early diffuse disease, overlap syndromes or pulmonary fibrosis. Current expert recommendations suggest a therapy with methotrexate for skin thickening or cyclophosphamide for acute alveolitis. However, more clinical trials with larger numbers of patients with recent onset SSc are needed.
N Blank; R Max; H-M Lorenz
Related Documents :
15961294 - Subjective and neurovegetative changes in healthy volunteers and panic patients perform...
24678754 - Influence of posture on the ventilatory pattern and the thoraco-abdominal kinematics of...
14648024 - All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic ...
19738174 - Neural damage associated with atopic diathesis: a nationwide survey in japan.
24504814 - Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, i...
3539814 - Perioperative stroke: the noncardiac surgery patient.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  45 Suppl 3     ISSN:  1462-0324     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-21     Completed Date:  2007-06-07     Revised Date:  2008-03-25    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  England    
Other Details:
Languages:  eng     Pagination:  iii42-4     Citation Subset:  AIM; IM    
Division of Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents / therapeutic use*
Scleroderma, Systemic / drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Antirheumatic Agents
Erratum In:
Rheumatology (Oxford). 2008 Feb;47(2):234-5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endothelin in human autoimmune diseases with renal involvement.
Next Document:  Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin rece...